07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Clinical News

Cx601: Phase I/II final data

Final data from an open-label, Spanish Phase I/II trial in 24 patients showed that Cx601 was safe with no treatment-related adverse events reported that indicated any clinical safety concerns at 6-month follow up. At week...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Cx601: Phase III started

TiGenix began the double-blind, placebo-controlled, European Phase III ADMIRE-CD trial to evaluate Cx601 in about 200 CD patients with complex perianal fistulas who failed previous treatment. TiGenix received a €5 million ($6.1 million) loan from...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

TiGenix autoimmune, gene/cell therapy news

The REGENER-AR consortium led by TiGenix received a €5.9 million ($7.7 million) grant from the European Commission's Framework Program 7 (FP7) to support development of TiGenix's Cx611 to treat rheumatoid arthritis (RA). TiGenix and its...
07:00 , May 9, 2011 |  BC Week In Review  |  Company News

Cellerix, TiGenix deal

Musculoskeletal company TiGenix completed its previously announced acquisition of Cellerix in a stock deal valued at €58.2 million ($86.2 million). As part of the acquisition, Eduardo Bravo, formerly CEO of Cellerix, becomes CEO of TiGenix....
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

Cellerix, TiGenix deal

Musculoskeletal company TiGenix will acquire Cellerix in a stock deal that values Cellerix at €58 million ($79.8 million). TiGenix will issue 44.8 million new TiGenix shares at €1.30. Prior to the close of the deal,...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Financial News

Cellerix proposes venture financing

Cellerix S.A. , Madrid, Spain   Business: Autoimmune, Dermatology, Gene/Cell therapy   Date announced: 2/25/11   Type: Venture financing   To be raised: Up to €18 milllion ($24.7 million)   Investors: Existing investors   Note:...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Financial News

TiGenix proposes rights offering

TiGenix N.V. (Euronext:TIG), Leuven, Belgium   Business: Musculoskeletal, Gene/Cell therapy   Date announced: 2/25/11   Type: Rights offering   To be raised: About €15 million ($20.5 million)   Shares: 15 million   Price: €1  ...
01:03 , Feb 26, 2011 |  BC Extra  |  Company News

TiGenix to acquire Cellerix

TiGenix N.V. (Euronext:TIG) will acquire fellow cell therapy company Cellerix S.A. (Madrid, Spain) in a stock deal that values Cellerix at EUR 58 million ($79.8 million). Cellerix shareholders will own 49% of the combined company,...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Clinical News

Cx601: Phase IIa data

Data from 22 evaluable patients in a Spanish Phase IIa trial showed that Cx601 was safe with only 5 patients experiencing adverse events considered potentially related to treatment. Additionally, Cx601-treated fistula tracts showed better closure...